Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
British Journal of Cancer
|
November 8, 2013
Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
L Heinzerling, M Baiter, S Kühnapfel, et al.
British Journal of Cancer
|
April 13, 2013
Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice
L Heinzerling, S Kühnapfel, D Meckbach, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2024
Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study
C Ertl, T Ruf, L Hammann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 24, 2024
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid
N Kramer, G Müller, S Zierold, et al.
Journal of Cancer Research and Clinical Oncology
|
June 16, 2017
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab
C Brüggemann, M C Kirchberger, S M Goldinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2016
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial
T K Eigentler, R Gutzmer, A Hauschild, et al.
Journal of Cancer Research and Clinical Oncology
|
July 5, 2023
Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)
Katharina C Kähler, S Hüning, D Nashan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2014
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival
S Ugurel, C Loquai, K Kähler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy
S Dugas-Breit, A Forschner, M Erdmann, et al.
Journal of Cancer Research and Clinical Oncology
|
April 16, 2023
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective
L Weiss, K Heinrich, D Zhang, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
British Journal of Cancer
|
November 8, 2013
Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
L Heinzerling, M Baiter, S Kühnapfel, et al.
British Journal of Cancer
|
April 13, 2013
Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice
L Heinzerling, S Kühnapfel, D Meckbach, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2024
Extracorporeal photopheresis vs. systemic immunosuppression for immune-related adverse events: Interim analysis of a prospective two-arm study
C Ertl, T Ruf, L Hammann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
February 24, 2024
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid
N Kramer, G Müller, S Zierold, et al.
Journal of Cancer Research and Clinical Oncology
|
June 16, 2017
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab
C Brüggemann, M C Kirchberger, S M Goldinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2016
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial
T K Eigentler, R Gutzmer, A Hauschild, et al.
Journal of Cancer Research and Clinical Oncology
|
July 5, 2023
Preferences of German and Swiss melanoma patients for toxicities versus melanoma recurrence during adjuvant treatment (GERMELATOX-A-trial)
Katharina C Kähler, S Hüning, D Nashan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2014
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival
S Ugurel, C Loquai, K Kähler, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy
S Dugas-Breit, A Forschner, M Erdmann, et al.
Journal of Cancer Research and Clinical Oncology
|
April 16, 2023
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective
L Weiss, K Heinrich, D Zhang, et al.
Page
of 4